Sky Century Investment (SKYI) Asset Utilization Ratio (2025 - 2026)
Sky Century Investment's (SKYI) quarterly Asset Utilization Ratio came in at 1.06 in Q2 2026, up 64.72% year-on-year from 0.65 in Q2 2025, and little changed on a QoQ basis from 1.07 in Q1 2026.
Sky Century Investment (SKYI) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
Sky Century Investment (SKYI) has 2 years of Asset Utilization Ratio data on file, last reported at 1.06 in Q2 2026.
- On a quarterly basis, Asset Utilization Ratio rose 64.72% year-over-year to 1.06 in Q2 2026; TTM through May 2026 was 1.06, a 64.72% increase from a year earlier, with the FY2025 full-year figure at 0.74, down 31.77% from the prior year.
- Asset Utilization Ratio for Q2 2026 stood at 1.06, roughly flat from 1.07 in the prior quarter.
- Over the last five years, Asset Utilization Ratio for SKYI reached as high as 1.07 in Q1 2026 and fell as low as 0.65 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 0.43 |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 0.62 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 0.46 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.43 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.39 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.65 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 0.37 |
| 10 | Sky Century Investment | 1.06 Mn | 1.06 Mn | 26,045.00 | 1.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 1.06 |
| Feb 28, 2026 | 1.07 |
| Nov 30, 2025 | 0.79 |
| Aug 31, 2025 | 0.65 |
| May 31, 2025 | 0.65 |